메뉴 건너뛰기




Volumn 83, Issue 3, 2016, Pages 181-186

Advances in the treatment of dyslipidemia

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT;

EID: 84973332928     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.83gr.16001     Document Type: Article
Times cited : (9)

References (22)
  • 1
    • 84897970506 scopus 로고    scopus 로고
    • 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
    • Erratum in: Circulation 2014; 129:S46-S48
    • Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129:S1-S45. Erratum in: Circulation 2014; 129:S46-S48
    • (2014) Circulation , vol.129 , pp. S1-S45
    • Stone, N.J.1    Robinson, J.G.2    Lichtenstein, A.H.3
  • 3
    • 84924662763 scopus 로고    scopus 로고
    • A proposal to incorporate trial data into a hybrid ACC/AHA algorithm for the allocation of statin therapy in primary prevention
    • Ridker PM, Rose L, Cook NR. A proposal to incorporate trial data into a hybrid ACC/AHA algorithm for the allocation of statin therapy in primary prevention. J Am Coll Cardiol 2015; 65:942-948
    • (2015) J Am Coll Cardiol , vol.65 , pp. 942-948
    • Ridker, P.M.1    Rose, L.2    Cook, N.R.3
  • 4
    • 84934277268 scopus 로고    scopus 로고
    • Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials
    • Mega JL, Stitziel NO, Smith JG, et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 2015; 385:2264-2271
    • (2015) Lancet , vol.385 , pp. 2264-2271
    • Mega, J.L.1    Stitziel, N.O.2    Smith, J.G.3
  • 5
    • 0027987849 scopus 로고
    • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
    • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389
    • (1994) Lancet , vol.344 , pp. 1383-1389
  • 6
    • 11144355354 scopus 로고    scopus 로고
    • Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    • Cannon CP, Braunwald E, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504
    • (2004) N Engl J Med , vol.350 , pp. 1495-1504
    • Cannon, C.P.1    Braunwald, E.2    McCabe, C.H.3
  • 7
    • 3142729178 scopus 로고    scopus 로고
    • Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    • Erratum in Circulation 2004; 110:763
    • Grundy SM, Cleeman JI, Merz CN, et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227-239. Erratum in Circulation 2004; 110:763
    • (2004) Circulation , vol.110 , pp. 227-239
    • Grundy, S.M.1    Cleeman, J.I.2    Merz, C.N.3
  • 8
    • 56749106312 scopus 로고    scopus 로고
    • Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
    • Ridker PM, Danielson E, Fonseca FAH, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207
    • (2008) N Engl J Med , vol.359 , pp. 2195-2207
    • Ridker, P.M.1    Danielson, E.2    Fonseca, F.A.H.3
  • 9
    • 0022549920 scopus 로고
    • A receptor-mediated pathway for cholesterol homeostasis
    • Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232:34-47
    • (1986) Science , vol.232 , pp. 34-47
    • Brown, M.S.1    Goldstein, J.L.2
  • 11
    • 78449281377 scopus 로고    scopus 로고
    • Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials
    • Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376:1670-1681
    • (2010) Lancet , vol.376 , pp. 1670-1681
    • Baigent, C.1    Blackwell, L.2    Emberson, J.3
  • 12
    • 79953836812 scopus 로고    scopus 로고
    • Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)
    • Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol 2011; 57:1666-1675
    • (2011) J Am Coll Cardiol , vol.57 , pp. 1666-1675
    • Hsia, J.1    MacFadyen, J.G.2    Monyak, J.3    Ridker, P.M.4
  • 13
    • 50949102416 scopus 로고    scopus 로고
    • Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes
    • Cannon CP, Giugliano RP, Blazing MA, et al; IMPROVE-IT Investigators. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008; 156:826-832
    • (2008) Am Heart J , vol.156 , pp. 826-832
    • Cannon, C.P.1    Giugliano, R.P.2    Blazing, M.A.3
  • 14
    • 84931411520 scopus 로고    scopus 로고
    • Ezetimibe added to statin therapy after acute coronary syndromes
    • Cannon CP, Blazing MA, Giugliano RP, et al for the IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372:2387-2397
    • (2015) N Engl J Med , vol.372 , pp. 2387-2397
    • Cannon, C.P.1    Blazing, M.A.2    Giugliano, R.P.3
  • 15
    • 84931033888 scopus 로고    scopus 로고
    • Are PCSK9 Inhibitors the next breakthrough in the cardiovascular field?
    • Giugliano RP, Sabatine MS. Are PCSK9 Inhibitors the next breakthrough in the cardiovascular field? J Am Coll Cardiol 2015; 65:2638-2651
    • (2015) J Am Coll Cardiol , vol.65 , pp. 2638-2651
    • Giugliano, R.P.1    Sabatine, M.S.2
  • 16
    • 33645103550 scopus 로고    scopus 로고
    • Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
    • Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354:1264-1272
    • (2006) N Engl J Med , vol.354 , pp. 1264-1272
    • Cohen, J.C.1    Boerwinkle, E.2    Mosley, T.H.3    Hobbs, H.H.4
  • 17
    • 33748661502 scopus 로고    scopus 로고
    • Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote
    • Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006; 79:514-523
    • (2006) Am J Hum Genet , vol.79 , pp. 514-523
    • Zhao, Z.1    Tuakli-Wosornu, Y.2    Lagace, T.A.3
  • 18
    • 34447299120 scopus 로고    scopus 로고
    • The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
    • Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007; 193:445-448
    • (2007) Atherosclerosis , vol.193 , pp. 445-448
    • Hooper, A.J.1    Marais, A.D.2    Tanyanyiwa, D.M.3    Burnett, J.R.4
  • 19
    • 84870478439 scopus 로고    scopus 로고
    • Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
    • Giugliano RP, Desai NR, Kohli P, et al; LAPLACE-TIMI 57 Investigators. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012; 380:2007-2017
    • (2012) Lancet , vol.380 , pp. 2007-2017
    • Giugliano, R.P.1    Desai, N.R.2    Kohli, P.3
  • 20
    • 84871326497 scopus 로고    scopus 로고
    • Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial
    • Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012; 308:2497-2506
    • (2012) JAMA , vol.308 , pp. 2497-2506
    • Sullivan, D.1    Olsson, A.G.2    Scott, R.3
  • 21
    • 84869220345 scopus 로고    scopus 로고
    • Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial
    • Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012; 126:2408-2417
    • (2012) Circulation , vol.126 , pp. 2408-2417
    • Raal, F.1    Scott, R.2    Somaratne, R.3
  • 22
    • 84926206074 scopus 로고    scopus 로고
    • Efficacy and safety of evolocumab in reducing lipids and cardiovascular events
    • Sabatine MS, Giugliano RP, Wiviott SD, et al; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1500-1509
    • (2015) N Engl J Med , vol.372 , pp. 1500-1509
    • Sabatine, M.S.1    Giugliano, R.P.2    Wiviott, S.D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.